SUBSCRIBE
SUBSCRIBE

Samus Therapeutics

NEWS
Samus Therapeutics has ceased operations.
Pictured: FDA sign at headquarters/Courtesy of Get
Drug Development
FDA Clears Samus Drug for Glioma Phase Ib Study
Clearance of the IND allows Samus to proceed with a Phase Ib trial to assess the safety, tolerability and pharmacokinetics of PU-AD in a small group of patients with recurrent malignant glioma.
May 11, 2021
 · 
2 min read
 · 
Brandon May
Alzheimer's Report September 2019
Drug Development
Alzheimer’s Disease Insight Report: Current Therapies, Drug Pipeline and Outlook
50 million people worldwide live with symptomatic Alzheimer’s, which has no cure. In honor of September 21st being World Alzheimer’s Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
September 18, 2019
 · 
36 min read
 · 
Chelsea Weidman Burke, M.S.
IN THE PRESS
Drug Development
Samus Therapeutics Announces First Patient Dosed in Phase 1b Study of Icapamespib in Recurrent Malignant Glioma
January 5, 2022
 · 
4 min read
Genetown
Samus Therapeutics Announces Study Publication in Communications Biology on the Importance of Epichaperome Inhibition for Enhancing the Vulnerability of Cancer Cells
December 1, 2021
 · 
4 min read
Genetown
Samus Therapeutics Announces Publication of Study on Epichaperome Chemical Probes in Nature Communications
September 2, 2021
 · 
4 min read
Policy
Samus Therapeutics Receives IND Clearance from FDA for PU-AD for the Treatment of Recurrent Malignant Glioma
May 11, 2021
 · 
4 min read
Drug Development
Samus Therapeutics Presents Phase 1 PU-AD Study Results at AAIC 2020 Advancing the Company’s Platform for Treating Neurodegenerative Diseases
July 29, 2020
 · 
5 min read
Genetown
Samus Therapeutics to Present at BIO CEO & Investor Conference
February 4, 2020
 · 
1 min read
Genetown
Study Published in Nature Communications Highlights the Role of the Epichaperome in Protein Connectivity-based Dysfunction in Alzheimer’s Disease
February 4, 2020
 · 
4 min read
Drug Development
Samus Therapeutics Announces Presentation of Phase 1b Study Evaluating Orally Administered PU-H71 with Ruxolitinib in Myelofibrosis at the ASH 2019 Annual Meeting
December 9, 2019
 · 
4 min read
Drug Development
Samus Therapeutics Launches PU-AD Clinical Program in Alzheimer’s Disease
July 23, 2019
 · 
5 min read
Drug Development
Samus Therapeutics Announces PU-H71 Granted Orphan Drug Designation and First Patient Dosed in Phase 1b Study in Myelofibrosis
June 13, 2018
 · 
6 min read
Load More